NCT00389441 - Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Thyroid Neoplasms

Interventions

DRUG

AG-013736

AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity

Trial Locations (26)

14263

Pfizer Investigational Site, Buffalo

20133

Pfizer Investigational Site, Milan

28033

Pfizer Investigational Site, Madrid

31008

Pfizer Investigational Site, Pamplona

33612

Pfizer Investigational Site, Tampa

56124

Pfizer Investigational Site, Pisa

67220

Pfizer Investigational Site, Witchita

67226

Pfizer Investigational Site, Wichita

80010

Pfizer Investigational Site, Aurora

92868

Pfizer Investigational Site, Orange

100021

Pfizer Investigational Site, Beijing

200233

Pfizer Investigational Site, Shanghai

210002

Pfizer Investigational Site, Nanjing

60637-1470

Pfizer Investigational Site, Chicago

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

02215

Pfizer Investigational Site, Boston

T6G 1Z2

Pfizer Investigational Site, Edmonton

N6A 4L6

Pfizer Investigational Site, London

H2L 4M1

Pfizer Investigational Site, Montreal

20001/200127

Pfizer Investigational Site, Shanghai

150 06

Pfizer Investigational Site, Prague

632 004

Pfizer Investigational Site, Vellore

44-101

Pfizer Investigational Site, Gliwice

02-781

Pfizer Investigational Site, Warsaw

G12 0YN

Pfizer Investigational Site, Glasgow